- IRAK DEGRADERS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same. The compounds include an IRAK binding moiety capable of binding to IRAK4 and a degradation inducing moiety (DIM). The DIM could be DTM a ligase binding moiety (LBM) or lysine mimetic. The compounds could be useful as IRAK protein kinase inhibitors and applied to IRAK mediated disorders.
- -
-
Paragraph 00920; 002436-002438
(2021/01/23)
-
- COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE
-
This invention is directed to, inter alia, compounds, methods, systems, and compositions for the maintenance, enhancement, and expansion of hematopoietic stem cells derived from one or more sources of CD34+ cells. Sources of CD34+ cells include bone marrow, cord blood, mobilized peripheral blood, and non-mobilized peripheral blood. Also provided herein are compounds of Formula I which are useful in maintaining, enhancing, and expanding of hematopoietic stem cells.
- -
-
Paragraph 0429
(2019/05/15)
-
- Discovery of ABBV/GLPG-3221, a Potent Corrector of CFTR for the Treatment of Cystic Fibrosis
-
Cystic fibrosis (CF) is a genetic disorder that affects multiple tissues and organs. CF is caused by mutations in the CFTR gene, resulting in insufficient or impaired cystic fibrosis transmembrane conductance regulator (CFTR) protein. The deletion of phenylalanine at position 508 of the protein (F508del-CFTR) is the most common mutation observed in CF patients. The most effective treatments of these patients employ two CFTR modulator classes, correctors and potentiators. CFTR correctors increase protein levels at the cell surface; CFTR potentiators enable the functional opening of CFTR channels at the cell surface. Triple-combination therapies utilize two distinct corrector molecules (C1 and C2) to further improve the overall efficacy. We identified the need to develop a C2 corrector series that had the potential to be used in conjunction with our existing C1 corrector series and provide robust clinical efficacy for CF patients. The identification of a pyrrolidine series of CFTR C2 correctors and the structure-activity relationship of this series is described. This work resulted in the discovery and selection of (2S,3R,4S,5S)-3-(tert-butyl)-4-((2-methoxy-5-(trifluoromethyl)pyridin-3-yl)methoxy)-1-((S)-tetrahydro-2H-pyran-2-carbonyl)-5-(o-tolyl)pyrrolidine-2-carboxylic acid (ABBV/GLPG-3221), which was advanced to clinical trials.
- Scanio, Marc J. C.,Searle, Xenia B.,Liu, Bo,Koenig, John R.,Altenbach, Robert,Gfesser, Gregory A.,Bogdan, Andrew,Greszler, Stephen,Zhao, Gang,Singh, Ashvani,Fan, Yihong,Swensen, Andrew M.,Vortherms, Timothy,Manelli, Arlene,Balut, Corina,Jia, Ying,Gao, Wenqing,Yong, Hong,Schrimpf, Michael,Tse, Chris,Kym, Philip,Wang, Xueqing
-
supporting information
p. 1543 - 1548
(2019/11/14)
-
- Substituted Pyrrolidines and Methods of Use
-
The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.
- -
-
Paragraph 1516; 1757
(2018/04/20)
-
- Process for the preparation of optically active carboxylic acids and amide intermediates
-
The present invention provides a process for the preparation of optically active carboxylic acids of the formula I* or II* STR1 in which X is an oxygen or sulfur atom and n is 1 or 2. The process comprises reacting a racemic carboxylic acid I or II or its derivatives with an optically active 2-amino-carboxylic acid ester to give the diastereomeric carboxylic acid amides, separating the diastereomers and, after cleavage of the amide bond, isolating the optically active carboxylic acids of the general formula I* or II*. The invention also provides certain novel optically active carboxylic acid amides and a tetrahydrothiopyran-2-carboxylic acid.
- -
-
-
- AN ELECTROCHEMICAL KETAL SYNTHESIS FROM 2-CARBOXY-2-ALLYL TETRAHYDROPYRANS
-
2-Substituted tetrahydropyranyl-2-carboxylates have been converted to mixed ketals by electrochemical oxidative decarboxylation.
- Wuts, Peter G. M.,Sutherland, Colin
-
p. 3987 - 3990
(2007/10/02)
-